Erica Lane Smith
Role not yet determined Is this you? Add your title
Formerly Arkansas Affiliated with UAMS through 2021; recent publications list Ambry Genetics (United States).
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Erica Lane Smith's research focuses on the development of small-molecule inhibitors targeting specific oncogenic proteins, particularly the rearranged during transfection (RET) proto-oncogene implicated in certain cancers. Her work involves drug discovery and development, with an emphasis on translating these findings into potential clinical applications. Smith has investigated pyrazoloadenine compounds as inhibitors of the RET lung cancer oncoprotein, employing fragment optimization approaches. Her collaborations include work with Katie R. Ryan, Brendan Frett, Noemi Garcia Garcia, and Baku Acharya at the University of Arkansas for Medical Sciences. Smith has 2 publications and 42 citations, with an h-index of 2. Her most recent publication was in 2026, indicating recent activity in her research pursuits.
Metrics
- h-index: 2
- Publications: 2
- Citations: 42
Selected Publications
-
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development (2021)
-
Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach (2021)
Collaboration Network
Top Collaborators
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
Similar Researchers
Based on overlapping research topics